Identification of a human cyclin D1-derived peptide that induces human cytotoxic CD4 T cells

PLoS ONE

Volumn 4, Issue 8, 2009, Pages

  Dao, Tao ^a   Korontsvit, Tatyana ^a   Zakhaleva, Victoria ^a   Haro, Kurtis ^a   Packin, Jonathan ^a   Scheinberg, David A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; EPITOPE; GAMMA INTERFERON; HLA A0201 ANTIGEN; HLA DR ANTIGEN; HLA DR B1 ANTIGEN; INTERLEUKIN 2; UNCLASSIFIED DRUG; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; PEPTIDE;

ANTIGEN BINDING; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION; GENE IDENTIFICATION; GENE NUMBER; GENE SEQUENCE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; T CELL DEPLETION; TUMOR IMMUNITY; UPREGULATION; AMINO ACID SEQUENCE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; MOLECULAR GENETICS; PHENOTYPE; TUMOR CELL LINE;

AMINO ACID SEQUENCE; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CYCLIN D1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC;

EID: 69449098245     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0006730     Document Type: Article

References (45)

1. Knudsen KE, Diehl JA, Haiman CA, Knudsen ES (2006) Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25: 1620-28.
2. Diehl JA, Cycling to cancer with cyclin D1 (2002) Cancer Biol Ther 1: 226-231.
3. Marzec M, Kasprzycka M, lai R, Gladden AB, Wlodarski P, et al. (2006) Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CD4 kinase activity. Blood 108 (5): 1744-1750.
4. Gladden AB, Woolery R, Aggarwal P, Wasik MA, Diehl JA (2006) Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25: 998-1007.
5. Gautschi O, Ratschiller D, Gugger M, Betticher DC, Heighway J (2007) Cyclin D1 in non-small cell lung cancer: A key driver of malignant transformation. J Lung Cancer 55: 1-14.
6. Gladden AB, Diehl JA (2005) Location, location, location: The role of cyclin D1 nuclear localization in cancer. J Cell Biochem 96: 906-913.
7. Lu F, Gladden AB, Diehl JA (2003) An alternative spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63: 7056-61, 2003.
8. Hosokawa Y, Gadd M, Smith AP, Koerner FC, Schmidt EV, et al. (1997) Cyclin D1 (PRAD1) alternative transcript b: full length cDNA cloning and expression in breast cancers. Cancer letter 113: 123-130.
9. Solomone DA, Wang Y, Fox SR, Lambeck TC, Giesting S, et al. (2003) Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. JBC 278 (32): 30339-30347.
10. Sadovnikova E, Jopling LA, Soo KS, Stauss HJ (1998) Generation of human tumor-reactive cytotoxic T cells against peptides presented by non-self HLA class I molecules. Eur J Immunol 28: 193-200.
11. Kondo E, Maeker B, Weinhrauch MR, Wickenhauser C, Zeng WY, et al. (2008) Cyclin D1-specific cytotoxic T lymphocytes are present in the repertoire of cancer patients: implications for cancer immunotherapy. Clin Cancer Res 14 (20): 6574-6579.
12. Slansky JE, Rattis FM, Boyd LF, Fahmy T, Jaffee EM, et al. (2000) Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-Peptide-TCR complex. Immunity 13: 529-538.
13. Renno T, lebecque S, Renard N, Saeland S, Vicari A (2003) What is the new in the field of cancer vaccines? Cell Mol Life Sci 60: 1296-1310.
14. Rosenberg SA, Yang JC, Restifo NP (2004) Cancer immunotherapy: moving beyond current vaccines. Nat Med 10: 909-915.
15. Rosenberg SA, Dudley ME (2004) Cancer regression in patients with metastatic melanoma after transfer of autologous antitumor lymphocytes. Proc Natl Acad Sci USA 101 (Suppl. 2): 14639-14645.
16. Melief CJM, van der Burg SH (2008) Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines. Nature Rev 8: 351-360.
17. Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Roberts W, Scheinberg DA (2005) Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses. Haematologica 90: 1324-1332.
18. van der Burg SH, Bijker MS, Welters MJP, Offringa R, Melief CMJ (2006) Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy. Advanced drug delivery Review 58: 916-930.
19. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300: 337-339.
20. Marzo AL, Kinnear BF, Lake RA, Frelinger JJ, Collins EJ, et al. (2000) Tumor-specific CD4+T cells have a major "post-licensing" role in CTL mediated antitumor immunity. J Immunol 165: 6047-6055.
21. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Padroll D, et al. (1998) The central role of CD4 (+) T cells in the antitumor immune response. J Exp Med 188: 2357-2368.
22. Gomez-Nunez M, Pinilla-Ibarz J, Dao T, May RJ, Pao M, et al. (2006) Peptide binding motif predictive algorithms correspond with experimental binding of leukemia vaccine candidate peptides to HLA-A*0201 molecules. Leu Res 30 (10): 1293-1298.
23. Castellino F, Germain RN (2006) Cooperation between CD4+ and CD8+ T cells: When, Where, and How. Annu Rev Immunol 24: 519-540.
24. Bijker MS, van den Eeden SJF, Franken KL, Melief CJM, Offringa R, et al. (2007) CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induces sustained CTL reactivity. J Immunol 179: 5033-5040.
25. May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, et al. (2007) Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 13 (15): 4547-4555.
26. Wilson EB, Livingstone AM (2008) Cutting edge: CD4+ T cell-derived IL-2 is essential for help-dependent primary CD8+ T cell responses. J Immunol 181: 7445-7448.
27. Dengjel J, Decker P, Schoor O, Altenberend F, Weinschenk T, et al. (2004) Identification of a naturally processed cyclin D1 T-helper epitope by a novel combination of HLA class II targeting and differential mass spectrometry. Eur J Immunol 34: 3644-3651.
28. Sun JC, Williams MA, Bevan MJ (2004) CD4-T cells are required for the maintenance, not programming, of memory CD8-T cells after acute infection. Nat Immunol 5: 927-933.
29. Janssen EM, Lemmens EE, Wolfe T, Christen U, von herrath MG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421 (6925): 852-856.
30. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ (1998) Tcell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (6684): 480-483.
31. Schuurhuis DH, Laban S, Toes RE, Ricciardi-Castagnoli P, Kleijmeer MJ, et al. (2000) Immature dendritic cells acquire CD8(+) cytotoxic T lymphocyte priming capacity upon activation by T helper cell-independent or -dependent stimuli. J Exp Med 192(1): 145-50.
32. Falo LD Jr, Colarusso LJ, Benacerraf B, Rock KL (1992) Serum proteases alter the antigenicity of peptides presented by class I major histocompatibility complex molecules. Proc Natl Acad Sci U S A 89 (17): 8347-50.
33. Amoscato AA, Prenovitz DA, Lotze MT (1998) Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J Immunol 161: 4023-4032.
34. Perez-Diez A, Joncker NT, Choi K, Chan WFN, Anderson CC, et al. (2007) CD4 T cells can be more efficient at tumor rejection than CD8 T cells. Blood 109 (12): 5346-5354.
35. Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, et al. (2008) Treatment of metastatic melanoma with autologous CD4+ T cells against NYESO-1. N Engl J Med 358: 2698-2703.
36. Heller KN, Gurer C, Munz C (2006) Virus-specific CD4+T cells: ready for direct attack. J Exp Med 203 (4): 805-808.
37. van leeuwen EM, Remmerswaal EB, Heemskerk MH, ten Berge IJ, van Lier RA (2006) Strong selection of virus-specific cytotoxic CD4+ T cell-clones during primary human cytomegalovirus infection. Blood 108: 3121-3127.
38. Hegde NR, Dunn C, Lewinsohn DM, Jarvis MA, Nelson JA (2005) Endogenous human cytomegalovirus gB is presented efficiently by MHC class II molecules to CD4+ CTL. J Exp Med 202: 1109-1119.
39. Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F (2004) The selection of tumor variants with altered expression of classical and nonclassical MHC I molecules: implications for tumor immune escape. Cancer Immunol Immunother 53: 904-910.
40. Colombo MP, Piconese S (2007) Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (11): 880-887.
41. Onizuka S, Tawara I, Shimizu I, Sakaguchi S, Fujita T, et al. (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 59: 3128-3133.
42. Asemissen AM, keilholz U, tenser S, Muller M, Walter S, et al. (2006) Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1. Clin Cancer Res 12(24): 7476-7482.
43. Dannull J, Su Z, Rizzier D, Yang BK, Coleman D, et al. (2005) Enhancement of vaccine-mediated anti-tumor immunity in cancer patients after depletion of regulator T cells. JCI 115: 3623-3633.
44. Nishikawa H, Qian F, Tsuji T, Ritter G, Old LJ, et al. (2006) Influence of CD4+CD25+ regulatory T cells on low/high-affinity CD4+ T cells following peptide vaccination. J Immunol 176: 6340-6346.
45. Nishikawa H, Tsuji T, Jager E, Briones G, Ritter G, et al. (2008) Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. Blood 111: 1404-1412.